These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 28841855)
41. [Curative radiotherapy of localized prostate cancer. Treatment methods and results]. Schwarz R Urologe A; 2003 Sep; 42(9):1212-20. PubMed ID: 14504754 [TBL] [Abstract][Full Text] [Related]
42. Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer. Nakai Y; Tanaka N; Asakawa I; Anai S; Miyake M; Hori S; Morizawa Y; Tatsumi Y; Hasegawa M; Fujii T; Fujimoto K J Radiat Res; 2019 Mar; 60(2):270-280. PubMed ID: 30576565 [TBL] [Abstract][Full Text] [Related]
43. The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy. Krishnan V; Delouya G; Bahary JP; Larrivée S; Taussky D BJU Int; 2014 Dec; 114(6):865-71. PubMed ID: 24274784 [TBL] [Abstract][Full Text] [Related]
44. Long-term biochemical outcomes using cesium-131 in prostate brachytherapy. Moran BJ; Rice SR; Chhabra AM; Amin N; Braccioforte M; Agarwal M Brachytherapy; 2019; 18(6):800-805. PubMed ID: 31427178 [TBL] [Abstract][Full Text] [Related]
45. [Five-year results of IMRT for prostate cancer - tumor control]. Odrážka K; Doležel M; Vaňásek J; Vaculíková M; Zouhar M; Šefrová J; Paluska P; Vošmik M; Kohlová T; Kolářová I; Broďák M; Navrátil P; Prošvic P; Hoffmann P; Hafuda A Klin Onkol; 2013; 26(6):415-20. PubMed ID: 24320590 [TBL] [Abstract][Full Text] [Related]
46. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471 [TBL] [Abstract][Full Text] [Related]
50. Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer. Ueno Y; Fukumori T; Kusuhara Y; Fukawa T; Tsuda M; Daizumoto K; Sasaki Y; Tomida R; Yamamoto Y; Yamaguchi K; Tonoiso C; Kubo A; Kawanaka T; Furutani S; Ikushima H; Takahashi M; Kanayama HO In Vivo; 2023; 37(2):738-746. PubMed ID: 36881090 [TBL] [Abstract][Full Text] [Related]
51. Low-dose-rate prostate brachytherapy: 4-8 week postimplant prostate-specific antigen a novel predictor of biochemical failure-free survival. Callaghan CM; Wang L; Alluri A; Lauve A; Boyer C; Russell W Brachytherapy; 2017; 16(6):1119-1128. PubMed ID: 28844821 [TBL] [Abstract][Full Text] [Related]
52. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer. Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022 [TBL] [Abstract][Full Text] [Related]
53. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial. Wallner K; Merrick G; True L; Sherertz T; Sutlief S; Cavanagh W; Butler W Radiother Oncol; 2005 Jun; 75(3):307-10. PubMed ID: 16086912 [TBL] [Abstract][Full Text] [Related]
54. Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. Berlin A; Ahmad AE; Chua MLK; Moraes FY; Jiang H; Komisarenko M; Trimilshina N; Raziee H; Hosni A; Murgic J; Chung P; Bristow RG; Finelli A Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):702-709. PubMed ID: 29249526 [TBL] [Abstract][Full Text] [Related]
55. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate. Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833 [TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Stock RG; Klein TJ; Cesaretti JA; Stone NN Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351 [TBL] [Abstract][Full Text] [Related]
57. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Shah C; Lanni TB; Ghilezan MI; Gustafson GS; Marvin KS; Ye H; Vicini FA; Martinez AA Brachytherapy; 2012; 11(6):441-5. PubMed ID: 22728157 [TBL] [Abstract][Full Text] [Related]
58. Long-term outcomes of radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer: Propensity score matched comparison. Urabe F; Miki K; Kimura T; Sasaki H; Tashiro K; Iwatani K; Matsukawa A; Aikawa K; Tsusumi Y; Morikawa M; Minato K; Sato S; Takahashi H; Aoki M; Egawa S Prostate; 2023 Feb; 83(2):135-141. PubMed ID: 36176043 [TBL] [Abstract][Full Text] [Related]
59. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure]. Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082 [TBL] [Abstract][Full Text] [Related]